Unlocking the Commercial Potential of Psychedelics
PSYCH is a data and insights platform for the psychedelic healthcare industry. Part of Psych Capital Plc.
The Psychedelics as Medicine Report: Third Edition
The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Follow us on Twitter
The Psychedelics as Medicine Report: Third Edition.
200+ pages of industry data and insight empowers investors, operators and regulators to make informed decisions.
Download your complimentary copy:
Psychedelics as Medicine: Third Edition | PSYCH
Download the most comprehensive account of the global psychedelics industry, with unparalleled market intelligence and i...
psych.global
👏🏼 👏🏼 👏🏼 https://twitter.com/psychglobal_/status/1527624041678262272
Leaders in psychedelic healthcare met at last week's PSYCH Symposium.
@MindMedco's Rob Barrow with Biomind Labs' Alejandro Antalich, @SmallPharma's Carol Routledge and @BeckleyPsytech's Cosmo Feilding Mellen.
Partnership opportunities: https://bit.ly/3wqrMMG
$MNMD $BMND $DMT
'Veterans were given controlled doses of MDMA and 68% experienced complete remission from PTSD.'
As social stigma dissipates, @MAPS' MDMA-assisted therapy for PTSD is set to be regulated in 2023: via @Forbes
Author Post: Psychedelics As Treatment Options For Mental Health
"More and more studies reveal that regulated doses of psychedelics like LSD, psilocybin (magic mushrooms), MDMA, or ...
bit.ly
Leaders in psychedelic healthcare met at last week's PSYCH Symposium.
@MindMedco's Rob Barrow with Biomind Labs' Alejandro Antalich, @SmallPharma's Carol Routledge and @BeckleyPsytech's Cosmo Feilding Mellen.
Partnership opportunities: https://bit.ly/3wqrMMG
$MNMD $BMND $DMT
Thanks @psychglobal_ for an excellent Symposium in London last week. Look forward to our next visit to #EU & #UK as @clairvoyantrx's #psilocybintherapy trial is initiated on each side of the Atlantic shortly
